Compare MMA & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMA | NVNO |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 16.7M |
| IPO Year | 2024 | N/A |
| Metric | MMA | NVNO |
|---|---|---|
| Price | $1.12 | $0.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 282.7K | ★ 423.3K |
| Earning Date | 01-01-0001 | 10-31-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $739,641.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 191.30 | N/A |
| 52 Week Low | $0.60 | $0.30 |
| 52 Week High | $3.07 | $5.62 |
| Indicator | MMA | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 44.59 | 45.56 |
| Support Level | $1.08 | $0.31 |
| Resistance Level | $1.25 | $0.39 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 23.03 | 57.88 |
Mixed Martial Arts Group Ltd formerly Alta Global Group Ltd is a technology company engaged in the provision and administration of mixed martial arts training programs, and gym programs. It provides subscription-based products and services, offering both B2B SaaS solutions and B2C products and programs, covering online engagement, online content, and immersive in-gym experiences. The company's business units are; Trainalta.com; Mixed Martial Arts.com; and Hype.Co, Mobile Marketing solution. Its Alta Platform serves as a comprehensive solution for martial arts and combat sports, offering a blend of four core products: the Warrior Training Program, UFC Fight Fit Program, Alta Academy, and the Alta Community.
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.